Patient disposition among patients with higher-risk CLL
| Parameter . | TN CLL (n = 320) . | R/R CLL (n = 488)∗ . | Total (N = 808) . |
|---|---|---|---|
| Follow-up, median (range), mo | 59.1 (1-82) | 44.3 (0-88) | 49.1 (0-88) |
| Patients remaining on treatment, n (%) | 164 (51) | 131 (27) | 295 (37) |
| Reasons for treatment discontinuation, n (%) | |||
| Progressive disease | 26 (8) | 149 (31) | 175 (22) |
| Adverse event | 44 (14) | 81 (17) | 125 (15) |
| Study terminated by sponsor | 42 (13) | 74 (15) | 116 (14) |
| Death | 11 (3) | 18 (4) | 29 (4) |
| Lost to follow-up | 2 (0.6) | 1 (0.2) | 3 (0.4) |
| Richter transformation | 1 (0.3) | 2 (0.4) | 3 (0.4) |
| Other† | 30 (9) | 32 (7) | 62 (8) |
| Parameter . | TN CLL (n = 320) . | R/R CLL (n = 488)∗ . | Total (N = 808) . |
|---|---|---|---|
| Follow-up, median (range), mo | 59.1 (1-82) | 44.3 (0-88) | 49.1 (0-88) |
| Patients remaining on treatment, n (%) | 164 (51) | 131 (27) | 295 (37) |
| Reasons for treatment discontinuation, n (%) | |||
| Progressive disease | 26 (8) | 149 (31) | 175 (22) |
| Adverse event | 44 (14) | 81 (17) | 125 (15) |
| Study terminated by sponsor | 42 (13) | 74 (15) | 116 (14) |
| Death | 11 (3) | 18 (4) | 29 (4) |
| Lost to follow-up | 2 (0.6) | 1 (0.2) | 3 (0.4) |
| Richter transformation | 1 (0.3) | 2 (0.4) | 3 (0.4) |
| Other† | 30 (9) | 32 (7) | 62 (8) |
R/R data set includes acalabrutinib plus obinutuzumab data from the CL-003 study in addition to the acalabrutinib monotherapy data from the CL-001, ELEVATE-R/R, and ASCEND studies.
Other includes physician decision (TN, n = 11; R/R, n = 15), withdrawal of consent (TN, n = 5; R/R, n = 11), pregnancy (TN, n = 1; R/R, n = 0), and other (TN, n = 13; R/R, n = 6).